Department of Pediatrics, Nantan General Hospital, Nantan City, Kyoto 629-0197, Japan.
Vaccine. 2011 Oct 13;29(44):7807-10. doi: 10.1016/j.vaccine.2011.07.105. Epub 2011 Aug 5.
Anticipating imminent licensure of rotavirus vaccine for use in Japan, we estimated the incidence of rotavirus hospitalization and calculated the direct medical cost associated with rotavirus hospitalization in a hospital that provided virtually exclusive pediatric beds to the local community adjacent to the northern outskirts of metropolitan Kyoto, Japan. For a 2 year period between September, 2008 and August, 2010, there were 103 hospitalizations due to acute gastroenteritis among children less than 5 years of age. Stool specimens from 77 (75%) of the 103 hospitalized patients were tested for rotavirus antigen, and 46 (60%) were positive. The proportion of rotavirus positives was 65% in the peak-season months (January-June) and 17% in the off-season months (July-December). By extrapolating the test results to those patients with acute gastroenteritis who were not tested, 13 additional cases were estimated to be rotavirus positive. Assuming that all patients with rotavirus gastroenteritis less than 5 years of age in the catchment (5532 according to the 2005 census) were admitted to this hospital, the annual incidence of rotavirus hospitalization was estimated to be 4.1 (testing-unadjusted)-5.3 (adjusted) per 1000 child-years. Thus, it was estimated that one child in 48 or one child in 37 born in this area would be hospitalized due to rotavirus gastroenteritis by the age of 5 years. The incidence of rotavirus hospitalization was similar to the rate in Ise city (4.9 per 1000 child-years), also in central Japan, and lower than the rate in Honjo city in northern Japan (13 per 1000 child-years). Nevertheless, the burden of rotavirus hospitalization was substantial, and the total direct medical cost was estimated to be 6.6 billion Japanese Yen (US$ 57 million). While economic analysis and comparisons with alternative preventive procedures may be necessary, this study provides the policymakers and pediatricians with further evidence that is necessary to decide whether to introduce rotavirus vaccines into the routine childhood immunization schedule in Japan.
预期日本即将批准使用轮状病毒疫苗,我们估算了轮状病毒住院病例的发生率,并计算了在京都市北部郊区附近一家为当地社区提供几乎全部儿科床位的医院中与轮状病毒住院相关的直接医疗费用。在 2008 年 9 月至 2010 年 8 月的 2 年期间,有 103 例 5 岁以下儿童因急性肠胃炎住院。对 103 名住院患儿的粪便标本进行了轮状病毒抗原检测,其中 77 例(75%)呈阳性。在流行季节(1 月至 6 月)轮状病毒阳性率为 65%,在非流行季节(7 月至 12 月)为 17%。通过将检测结果外推到未检测的急性肠胃炎患儿,估计另外 13 例为轮状病毒阳性。假设该流域(根据 2005 年人口普查为 5532 人)所有 5 岁以下轮状病毒肠胃炎患儿均住院治疗,轮状病毒住院年发生率估计为每 1000 名儿童年 4.1(未经调整)-5.3(调整后)。因此,估计该地区每 48 名或每 37 名儿童中就有 1 名会在 5 岁之前因轮状病毒肠胃炎住院。轮状病毒住院率与日本中部伊势市(每 1000 名儿童年 4.9 例)相似,低于日本北部本庄市(每 1000 名儿童年 13 例)。然而,轮状病毒住院的负担仍然很大,总直接医疗费用估计为 660 亿日元(5700 万美元)。虽然需要进行经济分析并与替代预防措施进行比较,但本研究为决策者和儿科医生提供了进一步的证据,有必要决定是否在日本将轮状病毒疫苗纳入常规儿童免疫接种计划。